305 results about "Lactic dehydrogenase" patented technology

The invention discloses an XZ-A26 bacterial strain for producing L-alanine with high yield, which has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.4036 and has the capacity of generating high-concentration L-alanine through fermentation. The XZ-A26 bacterial strain is constructed by the steps of: integrating an L-alanine dehydrogenase gene on thermophilic fatty bacillus chromosome on lactic dehydrogenase position on an escherichia coli ATCC8739 chromosome, then sequentially knocking out a pyruvate formate lyase gene, an alcohol dehydrogenase gene, an acetokinase gene, a fumaric acid reductase gene and an alanine racemase gene of the escherichia coli chromosome, and then carrying out continuous cell culture in a fermenting tank for obtaining agenetic engineering strain. The invention also relates to a construction method of the XZ-A26 bacterial strain and an application of the XZ-A26 bacterial strain in preparation of the L-alanine. According to the invention, the escherichia coli with the preservation number of CGMCC No.4036 for generating the high-concentration L-alanine through fermentation can be constructed by using a metabolic engineering method, and the yield of the L-alanine generated by using the XZ-A26 bacterial strain reaches up to 115g / L. The XZ-A26 bacterial strain is suitable for industrially producing the L-alanine.

The invention relates to the field of medicines and especially relates to an application of antiplatelet thrombolysin in preparation of a medicine for treating thrombotic thrombocytopenic purpura (TTP). The antiplatelet thrombolysin limits adhesion and aggregation of platelets, recovers levels of the platelets, erythrocytes and hemoglobin, reduces level of lactic dehydrogenase and effectively inhibits thrombocytopenia and cleaved-cell hemolyticanemia, thereby treating the TTP. The antiplatelet thrombolysin has great clinical application prospect.

The invention discloses application of Inonotus obliquus polysaccharide components in preventing and controlling chronic pancreatitis and belongs to the technical field of medicaments. The Inonotus obliquus polysaccharide components are applicable to preventing and controlling chronic pancreatitis. The Inonotus obliquus polysaccharide components which are 0.4g / kg of mouse weight are effective in increasing the content of superoxide dismutase in pancreatic glands of mice with chronic pancreatitis and decreasing accumulation of malondialdehyde and meanwhile are capable of reducing IL-1Beta and IFN-Nu in serum, and effective in decreasing the contents of amylase and lactic dehydrogenase and decreasing synthetic hydroxyproline. An application method of Inonotus obliquus polysaccharide components alleviate the condition of chronic pancreatitis in terms of immunity and metabolic regulation; compared with methods such as accumulated heat and dyspepsia conditioning in traditional Chinese medicine and medicated analgesia and surgery in western medicine, the method has the advantages that no toxic or side effect occurs, surgical pain is avoided, a treatment course is short, treatment is safe and convenient, and the effect of preventing and treating chronic pancreatitis in mice is significant.

The invention discloses double-gene knockout engineering bacteria and a construction method and an application thereof in fermentation production of 1,3-propylene glycol. A D-lactic dehydrogenase gene and an alpha-acetolactate synthetase gene in a genome of a wild type strain for production of 1,3-propylene glycol are knocked out to obtain the engineering strain; the wild type strain for production of 1,3-propylene glycol takes glycerol as a raw material for fermentation production of 1,3-propylene glycol. The engineering bacteria obtained after simultaneous knockout of the two genes of lactic dehydrogenase and acetolactate synthetase are applied in the process of fermentation-process production of 1,3-propylene glycol; the accounting proportion of 1,3-propylene glycol in a fermentation liquid in metabolites is increased, synthesis of lactic acid and 2,3-butylene glycol are simultaneously greatly reduced, and other by-products are not significantly increased. In the process of microbiological fermentation-process production of 1,3-propylene glycol, the role in improving the accounting proportion of 1,3-propylene glycol synthesized by the engineering bacteria and reducing the proportion of the synthesized by-products are played, the production cost is facilitated to be reduced, and the engineering bacteria have important application prospects.

The invention provides methods and materials related to the production of lactic acid. Specifically, the invention provides methods for producing lactic acid using a crabtree-negative yeast, such as of the Kluyveromyces, Pichia, Candida, Trichosporon and Yamadazmya genera, which have been transformed with a lactate dehydrogenase gene.

Yeast strains transformed with at least one copy of a gene coding for lactic dehydrogenase (LDH) and further modified for the production of lactic acid with high yield and productivities, are described.

The invention discloses construction and application of Escherichia coli engineering bacterium for immobilizing CO2 and producing malic acid, and belongs to the field of fermentation. The engineeringbacterium is a strain obtained by carrying out gene engineering modification on Escherichia coli MG1655. The genetic engineering transformation is as follows: 1, knocking out a fumarate reductase gene, a fumarase gene, a lactic dehydrogenase gene and an ethanol dehydrogenase gene, and carrying out free over-expression on formate dehydrogenase, acetyl coenzyme A synthetase, acylated acetaldehyde dehydrogenase, formaldehyde lyase, dihydroxyacetone kinase, malic enzyme and phosphorous acid oxidordeuctase so as to obtain a strain GH0407. The strain is used for fermentation production of malic acid, CO2 and glucose are used as co-substrates for anaerobic fermentation for 72 h, the malic acid yield reaches 39 g / L, the yield is 1.53 mol / mol, and malic acid is not accumulated in an original starting strain.

The invention discloses a fatigue-relieving traditional Chinese medicine health product, which is composed of the following seven traditional Chinese herbals: ginseng, processed rhizoma polygonati, wolfberry, raspberry, maca, epimedium, and cervus elaphus antler. The pharmacodynamic test result show that the health product can prolong the load swinging time of mice, the contents of hepatic glycogen and lactic dehydrogenase are increased, the contents of serum urea nitrogen and blood lactic acid are reduced, and the health product has a prominent fatigue relieving effect.